Exciting Results From HER2CLIMB in HER2+ mBC

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.

The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.

Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.

The top 5 OncLive TV videos of the week.

The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.

The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.

China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.